Atea Pharmaceuticals to Host Third Quarter 2023 Financial Results Conference Call on November 8, 2023
November 01 2023 - 7:00AM
Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a
clinical-stage biopharmaceutical company engaged in the discovery
and development of oral antiviral therapeutics for serious viral
diseases, today announced that it will host a live conference call
and audio webcast on Wednesday, November 8, 2023, at 4:30 p.m. ET
to report financial results for the third quarter ended September
30, 2023, and to provide a business update.
To access the live conference call, participants may register
here. The live audio webcast of the call will be available under
"Events and Presentations" in the Investor Relations section of the
Atea Pharmaceuticals website at ir.ateapharma.com. To participate
via telephone, please register in advance here. Upon registration,
all telephone participants will receive a confirmation email
detailing how to join the conference call, including the dial-in
number along with a unique passcode and registrant ID that can be
used to access the call. While not required, it is recommended that
participants join the call ten minutes prior to the scheduled
start. An archive of the audio webcast will be available on Atea
Pharmaceuticals’ website approximately two hours after the
conference call and will remain available for at least 90 days
following the event.
About Atea Pharmaceuticals
Atea is a clinical stage biopharmaceutical company focused on
discovering, developing and commercializing oral therapies to
address the unmet medical needs of patients with serious viral
infections. Leveraging the Company’s deep understanding of
antiviral drug development, nucleos(t)ide chemistry, biology,
biochemistry and virology, Atea is developing novel product
candidates to treat single stranded ribonucleic acid, or ssRNA,
viruses, which are a prevalent cause of serious viral diseases.
Atea plans to continue to build its pipeline of antiviral product
candidates through using its internal discovery capabilities
augmented by in-licensing. Currently, Atea is focused on the
development of orally-available antiviral agents for serious viral
infections, including severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2), the virus that causes COVID-19, and hepatitis C
virus (HCV). For more information, please visit
www.ateapharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. All statements contained in this press release that do not
relate to matters of historical fact should be considered
forward-looking statements, including without limitation statements
regarding the timing of Atea’s earnings call for the quarter ended
June 30, 2023 and the timing of posting of the earnings call audio
webcast to Atea’s website. These statements are neither promises
nor guarantees, but involve known and unknown risks, uncertainties
and other important factors that may cause our actual results,
performance or achievements to be materially different from any
future results, performance or achievements expressed or implied by
the forward-looking statements, including, but not limited to the
important factors discussed under the caption “Risk Factors” in our
Annual Report on Form 10-K for the year ended December 31, 2022 and
our other filings with the SEC. Any such forward-looking statements
represent management’s estimates as of the date of this press
release. These forward-looking statements should not be relied upon
as representing the Company’s views as of any date subsequent to
the date of this press release. While the Company may elect to
update such forward-looking statements at some point in the future,
except as required by law, it disclaims any obligation to do so,
even if subsequent events cause our views to change.
Contacts
Jonae BarnesSVP, Investor Relations and Corporate
Communications617-818-2985Barnes.jonae@ateapharma.com
Will O’ConnorStern Investor Relations
212-362-1200will.oconnor@sternir.com
Atea Pharmaceuticals (NASDAQ:AVIR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Atea Pharmaceuticals (NASDAQ:AVIR)
Historical Stock Chart
From Apr 2023 to Apr 2024